Diclofenac Sodium is a drug owned by Falcon Pharmaceuticals Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 16, 2014. Details of Diclofenac Sodium's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5603929 | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
Nov, 2014
(10 years ago) |
Expired
|
| US5653972 | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
Nov, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Diclofenac Sodium is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Diclofenac Sodium's family patents as well as insights into ongoing legal events on those patents.
Diclofenac Sodium's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Diclofenac Sodium's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 16, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Diclofenac Sodium Generic API suppliers:
Diclofenac Sodium is the generic name for the brand Diclofenac Sodium. 41 different companies have already filed for the generic of Diclofenac Sodium, with Rubicon having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Diclofenac Sodium's generic
Alternative Brands for Diclofenac Sodium
Diclofenac Sodium which is used for treating or controlling ocular inflammation in the affected eye., has several other brand drugs using the same active ingredient (Diclofenac Sodium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Fougera Pharms |
| |
| Horizon |
| |
| Javelin Pharms Inc |
| |
| Nuvo Pharms Inc |
| |
| Pfizer |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Diclofenac Sodium, Diclofenac Sodium's active ingredient. Check the complete list of approved generic manufacturers for Diclofenac Sodium
About Diclofenac Sodium
Diclofenac Sodium is a drug owned by Falcon Pharmaceuticals Ltd. It is used for treating or controlling ocular inflammation in the affected eye. Diclofenac Sodium uses Diclofenac Sodium as an active ingredient. Diclofenac Sodium was launched by Falcon Pharms in 1998.
Approval Date:
Diclofenac Sodium was approved by FDA for market use on 04 May, 1998.
Active Ingredient:
Diclofenac Sodium uses Diclofenac Sodium as the active ingredient. Check out other Drugs and Companies using Diclofenac Sodium ingredient
Treatment:
Diclofenac Sodium is used for treating or controlling ocular inflammation in the affected eye.
Dosage:
Diclofenac Sodium is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | SOLUTION/DROPS | Discontinued | OPHTHALMIC |